Neurologic and Psychiatric Comorbidities Associated with Drug Resistant Epilepsy
Abstract number :
1.272
Submission category :
6. Cormorbidity (Somatic and Psychiatric)
Year :
2022
Submission ID :
2204177
Source :
www.aesnet.org
Presentation date :
12/3/2022 12:00:00 PM
Published date :
Nov 22, 2022, 05:23 AM
Authors :
Fahham Asghar, MD – University of Toledo COM LS; Sidra Saleem, MD – PGY-3 Resident, Neurology, University of Toledo COM LS; Elysia James, MD – Assistant Professor, Neurology, University of Toledo COM LS; Hira Pervez, MD – PGY-2 Resident, Neurology, University of Toledo COM LS; Naeem Mahfooz, MD – Assistant Professor, Neurology, University of Toledo COM LS; Anum Riaz, MD – Assistant Professor, Neurology, University of Toledo COM LS; Alaina Zhang, Medical Student – Neurology – University of Toledo COM LS; Ajaz Sheikh, MD – Associate Professor, Neurology, University of Toledo COM LS; Imran Ali, MD – Professor, Neurology, University of Toledo COM LS
Rationale: Approximately one-third of persons with epilepsy (PWE) develop drug resistant epilepsy (DRE). The aim of this study was to estimate the prevalence of DRE in our patient population, correlation with comorbid behavioral neurologic and psychiatric conditions, and identify any factors that may be predictive of seizure control in patients with epilepsy.
Methods: This was a cross-sectional study with data collected from patients at initial presentation to a tertiary care epilepsy center. Patients were grouped based on seizure control into Drug Resistant Epilepsy (DRE) and seizure free for more than 6 months. DRE was defined as patients not achieving seizure control after adequate trial of at least two anti-seizure medications. Patients being seizure free for more than 6 months on their initial visit were used as a comparison group.
Results: There were 524 patients in our cohort, 46% men and 54% women; mean age was 45.1±20 years. Out of 524 patients, 169 (32.3%) patients had DRE while 355 (67.7%) patients were free of seizures for more than 6 months. Significant differences (p< 0.05) were found between DRE and patients who were seizure free for more than 6 months. A higher prevalence and odds of the following neurologic and psychiatric conditions was noted in DRE patients: attention deficit hyperactivity disorder (ADHD): 13.6% vs. 5.9%, generalized anxiety disorder (GAD): 21.3% vs. 13.5%, developmental disability: 28.9% vs. 11.2%, learning disability 29.5% vs. 13.8% and autism 8.8% vs. 3% (Table 1). A trend was found for DRE patients to be younger at seizure onset._x000D_
_x000D_
Patients with DRE had higher odds of having the following comorbidities: ADHD (OR= 2.3; 95% CI = 1.3-4), GAD (OR =1.5, 95% CI=1.1-2.3), developmental disability (OR= 2.5, 95% CI = 1.7-3.6), learning disability (OR=2.1, 95% CI= 1.4-2.9) and autism (OR=2.8, 95% CI= 1.3-5.9). Statistically significant differences were not found for other comorbid conditions (Table 2).
Cormorbidity (Somatic and Psychiatric)